Journal of Clinical Oncology 临床肿瘤· Lieke Mous·· 14 天前AI 评分45
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53, STAG2, and CDKN2A Alterations
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53, STAG2, and CDKN2A Alterations
AI 导读
一项针对Ewing肉瘤II/III期临床试验的循环肿瘤DNA分析发现,TP53、STAG2和CDKN2A突变的患者为高风险群体。
来源:Journal of Clinical Oncology 临床肿瘤 · ascopubs.org